Industry
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
Biofarma Group's R&D to support people in the pre-depressive phase.
Ensemble No.3 (ENS-003) is in development to address vulvovaginal candidiasis – a vaginal yeast infection for which antifungal treatments offer limited protection from recurrence.
A large Korean population study provides scientific evidence that altering the gut microbiome composition through dietary habit change can help prevent and manage the hypertension.
Industry
Sponsored by
The 6’-SL HMO from Chr. Hansen is approved for highest use levels in infant formula and follow-on formula in EU.
Industry
Sponsored by
The French family company has acquired 100% of TargEDys’ shares, to consolidate the group’s strong ambition in the Microbiome and accelerate TargEDys’ development globally.
Industry
Sponsored by
Tensred plus®: an innovative formula to combat pre-hypertension.
Key outputs and innovations of direct relevance to food and agriculture from the H2020 funded MASTER project.
This partnership aims to leverage Microba's advanced technology platform for measuring the human gut microbiome to discover novel biomarkers for pancreatic cancer detection.
